This post was originally published on this site
Biomarin Pharma announced earnings per share of $4.01 on revenue of $476.8M. Analysts polled by Investing.com anticipated EPS of $-0.11 on revenue of $454.64M.
Biomarin Pharma shares are down 57.55% from the beginning of the year, still down 43.09% from its 52 week high of $131.95 set on July 21. They are under-performing the S&P 500 which is up 8.67% from the start of the year.
Biomarin Pharma’s report follows an earnings beat by J&J on October 13, who reported EPS of $2.2 on revenue of $21.08B, compared to forecasts EPS of $1.98 on revenue of $20.2B.
Thermo Fisher Scientific had beat expectations on October 21 with third quarter EPS of $5.63 on revenue of $8.52B, compared to forecast for EPS of $4.33 on revenue of $7.65B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
